Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.

Status:
Completed

Trial end date:
2016-10-26

Target enrollment:

Participant gender:

This is a multi-center, open-label, non-randomized, phase I study

Phase 1

Novartis Pharmaceuticals

Letrozole